Abstract:3607 Background: Although the anti-tumor properties of vitamin D in colorectal cancer (CRC) have been broadly reported, its potential role as a tumor microenvironment (TME) immunomodulator has not been well established. Vitamin D receptor (VDR) and CYP27B1 (1-α-hydroxylase; required to convert vitamin D to its active form) are critical factors in the vitamin D signaling pathway and harbor prognostic significance for CRC. Pre-clinical studies suggest that higher stromal VDR expression enhances chemotherapy efficacy. To characterize the effects of vitamin D on the TME in humans, we conducted a randomized placebo-controlled trial of preoperative high-dose vitamin D supplementation in stage I-III colon cancer patients. Methods: Forty-two patients were randomized to receive vitamin D3 50,000 IU/day x 7 days followed by 10,000 IU/day versus placebo prior to resection. Paired pre-treatment biopsy specimens and post-treatment surgical resection specimens from 19 patients who completed the assigned treatment and had sufficient tissue for analysis were collected for spatially-resolved immune cell profiling and evaluation of VDR and CYP27B1 expression using custom multiplex immunofluorescence. Blood samples were collected pre- and post-treatment to assess plasma 25-hydroxyvitamin D [25(OH)D] levels. Linear mixed effects models were used to compare tissue parameters; plasma 25(OH)D level changes were assessed using the Wilcoxon rank-sum test. Results: Patients randomized to high-dose vitamin D had increased post-treatment plasma 25(OH)D (median 18.0 to 63.6 (ng/ml)) whereas placebo-randomized patients did not (median 19.1 to 18.6 (ng/ml)) ( p <0.001). Analysis of both biopsy and resection tissue revealed highly heterogeneous VDR and CYP27B1 expression. VDR expression was highest in tumor cells, followed by immune and then stromal cells. Although resection tissue from vitamin D-treated patients showed lower VDR expression than specimens from placebo-treated patients in all cells ( p= 0.03), VDR was preferentially expressed by tumor cells at the tumor invasive front compared to tumor center in the vitamin D arm, while the opposite was observed in the placebo arm. Vitamin D supplementation did not alter CYP27B1 expression. While treatment did not change total immune cell density, resection tissue from vitamin D-treated patients had higher overall CD3 + CD8 + T cell density ( p= 0.04), particularly CD3 + CD8 + memory T cell density ( p= 0.02). Additionally, vitamin D supplementation led to greater co-localization between CD3 + CD8 + T cells and tumor cells ( p< 0.001) compared to placebo. Conclusions: In patients with stage I-III CRC, vitamin D supplementation led to changes in vitamin D pathway signaling and evidence of an anti-tumor effect in the TME. Further investigation into the underlying mechanism of action is warranted. Clinical trial information: NCT02172651 .

Dietary vitamin D intake and risk of colorectal cancer according to vitamin D receptor expression in tumors and their surrounding stroma

Vitamin D receptor expression is associated with colon cancer in ulcerative colitis

Impact of vitamin d on the colon tumor immune microenvironment: Results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer

Vitamin D Status after Colorectal Cancer Diagnosis and Patient Survival According to Immune Response to Tumour.

Effect of Vitamin D Receptor on Plasma Pro-inflammatory Cytokines Levels and Gut Microbiota in Patients with Colorectal Cancer

Effect of Vitamin D Supplements on Relapse of Digestive Tract Cancer with Tumor Stromal Immune Response: A Secondary Analysis of the AMATERASU Randomized Clinical Trial

Expression and Regulation Mechanism of Vitamin D Receptor in Colorectal Cancer

Adequate Vitamin D Level Associated with Reduced Risk of Sporadic Colorectal Cancer.

The clinical significance of vitamin D levels and vitamin D receptor mRNA expression in colorectal neoplasms

Vitamin D intake as well as circulating 25-hydroxyvitamin D level and risk for the incidence and recurrence of colorectal cancer precursors: A meta-analysis

Vitamin D treatment induces in vitro and ex vivo transcriptomic changes indicating anti‐tumor effects

Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence

Additively Protective Effects of Vitamin D and Calcium Against Colorectal Adenoma Incidence, Malignant Transformation and Progression: A Systematic Review and Meta-Analysis.

Circulating Vitamin D and Colorectal Cancer Risk: an International Pooling Project of 17 Cohorts.

Vitamin D Receptor Gene Polymorphisms and Colorectal Cancer Risk: A Systematic Meta-Analysis

Serum Vitamin D Concentration, Vitamin D‐related Polymorphisms, and Colorectal Cancer Risk

Vitamin D Receptor Gene Polymorphisms and the Risk of Colorectal Cancer in a Chinese Population

Association Between Vitamin Intake and Colorectal Cancer: Evidence from NHANES Data

Vitamin D Status and Survival in Stage II-III Colorectal Cancer

Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts